Rezvan Hosseinzadeh

Rezvan Hosseinzadeh

Auto-generated profile, based on publicly available information

Rezvan Hosseinzadeh

Babol university of medical science

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2021 in Reviews in Medical Virology
Verified
Journal Article
Open access
PDF file
ZAZeinab Mohseni Afshar
Zeinab Mohseni Afshar
ABArefeh Babazadeh
Arefeh Babazadeh
AJAlireza Janbakhsh
Alireza Janbakhsh
FMFeizollah Mansouri
Feizollah Mansouri
TSTerence T. Sio
Terence T. Sio
Soheil EbrahimpourSoheil Ebrahimpour
Soheil Ebrahimpour
Summary: Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a crucial step in ending the current worldwide pandemic. However, several particularly vulnerable groups in the population were not included in sufficient numbers in coronavirus disease 2019 (Covid‐19) vaccine trials. Therefore, as science advances, the advice for vaccinating these special populations against Covid‐19 will continue to evolve. This focused review provides the latest recommendations and considerations for these special populations (i.e., patients with rheumatologic and autoimmune disorders, cancer, transplant recipients, chronic liver diseases, end‐stage renal disease, neurologic disorders, psychiatric disorders, diabetes mellitus, obesity, cardiovascular diseases, chronic obstructive pulmonary disease, human immunodeficiency virus, current smokers, pregnant and breastfeeding women, the elderly, children, and patients with allergic reactions) using the currently available research evidence.

23 December 2021 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
ZAZeinab Mohseni Afshar
Zeinab Mohseni Afshar
RHRezvan Hosseinzadeh
Rezvan Hosseinzadeh
MBMohammad Barary
Mohammad Barary
Soheil EbrahimpourSoheil Ebrahimpour
Soheil Ebrahimpour
AAAmirmasoud Alijanpourotaghsara
Amirmasoud Alijanpourotaghsara
ABArefeh Babazadeh
Arefeh Babazadeh
A novel coronavirus, or severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), was identified as the causative agent of coronavirus disease 2019 (COVID‐19). In early 2020, the World Health Organization declared COVID‐19 the sixth public health emergency of international concern. The COVID‐19 pandemic has substantially affected many groups within the general population, but particularly those with extant clinical conditions, such as having or being treated for cancer. Cancer patients are at a higher risk of developing severe COVID‐19 since the malignancy and chemotherapy may negatively affect the immune system, and their immunocompromised condition also increases the risk of infection. Substantial international efforts are currently underway to develop specific methods for diagnosing and treating COVID‐19. However, cancer patients’ risk profiles, management, and outcomes are not well understood. Thus, the main objective of this review is to discuss the relevant evidence to understand the prognosis of COVID‐19 infections in cancer patients more clearly, as well as helping to improve the clinical management of these patients.

27 May 2022 in Reviews in Medical Virology
Verified
Journal Article
Closed access
ZAZeinab Mohseni Afshar
Zeinab Mohseni Afshar
MBMohammad Barary
Mohammad Barary
ABArefeh Babazadeh
Arefeh Babazadeh
APAli Tavakoli Pirzaman
Ali Tavakoli Pirzaman
RHRezvan Hosseinzadeh
Rezvan Hosseinzadeh
Soheil EbrahimpourSoheil Ebrahimpour
Soheil Ebrahimpour

2 February 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
ZAZeinab Mohseni Afshar
Zeinab Mohseni Afshar
APAli Tavakoli Pirzaman
Ali Tavakoli Pirzaman
BKBardia Karim
Bardia Karim
SAShiva Rahimipour Anaraki
Shiva Rahimipour Anaraki
RHRezvan Hosseinzadeh
Rezvan Hosseinzadeh
Soheil EbrahimpourSoheil Ebrahimpour
Soheil Ebrahimpour
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, there have been multiple peaks of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus virus 2) infection, mainly due to the emergence of new variants, each with a new set of mutations in the viral genome, which have led to changes in the pathogenicity, transmissibility, and morbidity. The Omicron variant is the most recent variant of concern (VOC) to emerge and was recognized by the World Health Organization (WHO) on 26 November 2021. The Omicron lineage is phylogenetically distinct from earlier variants, including the previously dominant Delta SARS-CoV-2 variant. The reverse transcription–polymerase chain reaction (RT–PCR) test, rapid antigen assays, and chest computed tomography (CT) scans can help diagnose the Omicron variant. Furthermore, many agents are expected to have therapeutic benefits for those infected with the Omicron variant, including TriSb92, molnupiravir, nirmatrelvir, and their combination, corticosteroids, and interleukin-6 (IL-6) receptor blockers. Despite being milder than previous variants, the Omicron variant threatens many lives, particularly among the unvaccinated, due to its higher transmissibility, pathogenicity, and infectivity. Mounting evidence has reported the most common clinical manifestations of the Omicron variant to be fever, runny nose, sore throat, severe headache, and fatigue. This review summarizes the essential features of the Omicron variant, including its history, genome, transmissibility, clinical manifestations, diagnosis, management, and the effectiveness of existing vaccines against this VOC.

30 June 2023 in Clinical and Translational Science
Verified
Journal Article
Open access
ZAZeinab Mohseni Afshar
Zeinab Mohseni Afshar
APAli Tavakoli Pirzaman
Ali Tavakoli Pirzaman
RHRezvan Hosseinzadeh
Rezvan Hosseinzadeh
ABArefeh Babazadeh
Arefeh Babazadeh
MMMohamad Ali Taghizadeh Moghadam
Mohamad Ali Taghizadeh Moghadam
Soheil EbrahimpourSoheil Ebrahimpour
Soheil Ebrahimpour
Coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), can manifest itself in several ways, including coagulopathy and thrombosis. These complications can be the first and sometimes only manifestations of SARS‐CoV‐2 infection and can occur early or late in the course of the disease. However, these symptoms are more prevalent in hospitalized patients with venous thromboembolism, particularly those admitted to intensive care units. Moreover, various forms of arterial and venous thrombosis, or micro‐ or macro‐vasculature embolisms, have been reported during the current pandemic. They have led to harmful consequences, such as neurological and cardiac events, nearly all resulting from the hypercoagulable state caused by this viral infection. The severe hypercoagulability observed in patients with COVID‐19 accounts for most cases of the disease that become critical. Therefore, anticoagulants seem to be one of the most vital therapeutics for treating this potentially life‐threatening condition. In the current paper, we present a thorough review of the pathophysiology of COVID‐19‐induced hypercoagulable state and the use of anticoagulants to treat SARS‐CoV‐2 infections in different patient groups, as well as their pros and cons.

21 June 2022 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
RHRezvan Hosseinzadeh
Rezvan Hosseinzadeh
MBMohammad Barary
Mohammad Barary
HMHamed Mehdinezhad
Hamed Mehdinezhad
TSTerence T. Sio
Terence T. Sio
FLFlorian Langer
Florian Langer
SKSahar Khosravi
Sahar Khosravi
Severe side effects after vaccination with coronavirus disease 2019 (COVID‐19) vaccines are rare but can be fatal. To date, vaccine‐induced immune thrombotic thrombocytopenia (VITT) cases have been reported after injection of mRNA and adenoviral vectors COVID‐19 vaccines. Here, we report the second suspected case of VITT after vaccination with the Sinopharm vaccine, an inactive vaccine. The Key Clinical Question was to determine whether inactivated COVID‐19 vaccines could induce VITT and how to diagnose and treat such cases. Our patient developed deteriorating symptoms the day after vaccination and was admitted to the emergency department on day 5 after vaccination. After performing laboratory analysis, thrombosis with thrombocytopenia was suggested, further confirmed by highly positive anti‐heparin–platelet factor 4 antibodies assay and color Doppler ultrasonography. He was then treated with high‐dose intravenous immunoglobulin, corticosteroid, and nonheparin anticoagulant.